Tiffany N. Caza, Arkana Laboratories, Little Rock, Arkansas
Clarissa A. Cassol, Arkana Laboratories, Little Rock, Arkansas
Nidia Messias, Arkana Laboratories, Little Rock, Arkansas
Andrew Hannoudi, University of Michigan, Ann Arbor, Michigan
Randy S. Haun, Arkana Laboratories, Little Rock, Arkansas
Patrick D. Walker, Arkana Laboratories, Little Rock, Arkansas
Rebecca M. May, Arkana Laboratories, Little Rock, Arkansas
Regan M. Seipp, DuPage Medical Group, Naperville, Illinois
Elizabeth J. Betchick, Methodist LeBonheur Healthcare-Germantown, Germantown, Tennessee
Hassan Amin, The Kidney Group of Memphis, Memphis, Tennessee
Mandolin S. Ziadie, Memorial Regional Hospital, Miramar, Florida
Michael Haderlie, Iowa Kidney Institute, Bingham Memorial Hospital, Blackfoot, Idaho
Joy Eduwu-Okwuwa, Permian Nephrology Associates, Midland, Texas
Irina Vancea, Southern Colorado Nephrology Associates, Pueblo, Colorado
Melvin Seek, Ocala Kidney Group, Ocala, Florida
Essam B. Elashi, Firelands Physicians Group, Sandusky, Ohio
Ganesh Shenoy, Lee Kidney Center, Lehigh Acres, Florida
Sayeed Khalillullah, North Florida Nephrology Associates, Tallahassee, Florida
Jesse A. Flaxenburg, Pikes Peak Nephrology, Colorado Springs, Colorado
John Brandt, Division of Nephrology, University of New Mexico, Albuquerque, New Mexico
Matthew J. Diamond, Nephrology Associates (Augusta), Augusta, Georgia
Adam Frome, Kidney Specialists of North Houston, Shenandoah, Texas
Eugene H. Kim, Kidney and Hypertension Specialists PLLC, Manassas, Virginia
Gregory Schlessinger, Rocky Mountain Kidney Care, Lone Tree, Colorado
Erlandas Ulozas, Carle Nephrology, Urbana, Illinois
Janice L. Weatherspoon, Southern Crescent Nephrology, Stockbridge, Georgia
Ethan Thomas Hoerschgen, Springfield Nephrology Associates, Springfield, Missouri
Steven L. Fabian, Rocky Mountain Kidney Care, Aurora, Colorado
Sung Yong Bae, East Tennessee Nephrology, Knoxville, Tennessee
Bilal Iqbal, Kidney Specialists of Southern Nevada, Las Vegas, Nevada
Kanwalijit K. Chouhan, Iowa Kidney Physicians P.C., Des Moines, Iowa
Zeina Karam, Mercy Clinic Nephrology, Washington, Missouri
James T. Henry, Renal Care Associates, Fort Smith, Arkansas
Christopher P. Larsen, Arkana Laboratories, Little Rock, Arkansas

Document Type


Publication Date



Background: Immune responses to vaccination are a known trigger for a new onset of glomerular disease or disease flare in susceptible individuals. Mass immunization against SARS-CoV-2 in the COVID-19 pandemic provides a unique opportunity to study vaccination-associated autoimmune kidney diseases. In the recent literature, there are several patient reports demonstrating a temporal association of SARS-CoV-2 immunization and kidney diseases.

Methods: Here, we present a series of 29 cases of biopsy-proven glomerular disease in patients recently vaccinated against SARS-CoV-2 and identified patients who developed a new onset of IgA nephropathy, minimal change disease, membranous nephropathy, ANCA-associated GN, collapsing glomerulopathy, or diffuse lupus nephritis diagnosed on kidney biopsies postimmunization, as well as recurrent ANCA-associated GN. This included 28 cases of

Results: The patients with collapsing glomerulopathy were of Black descent and had two

Conclusions: Glomerular disease to vaccination is rare, although it should be monitored as a potential adverse event.

Publication Title








First Page


Last Page